nodes	percent_of_prediction	percent_of_DWPC	metapath
Clofedanol—HRH1—Monoamine GPCRs—ADRA1D—polycystic ovary syndrome	0.0357	0.0548	CbGpPWpGaD
Clofedanol—HRH1—Monoamine GPCRs—ADRA1B—polycystic ovary syndrome	0.0347	0.0533	CbGpPWpGaD
Clofedanol—HRH1—Amine ligand-binding receptors—ADRA1D—polycystic ovary syndrome	0.03	0.0461	CbGpPWpGaD
Clofedanol—HRH1—Amine ligand-binding receptors—ADRA1B—polycystic ovary syndrome	0.0292	0.0448	CbGpPWpGaD
Clofedanol—Loperamide—POMC—polycystic ovary syndrome	0.0272	0.0783	CrCbGaD
Clofedanol—HRH1—Monoamine GPCRs—ADRA1A—polycystic ovary syndrome	0.0263	0.0404	CbGpPWpGaD
Clofedanol—HRH1—Monoamine GPCRs—ADRB3—polycystic ovary syndrome	0.0253	0.0389	CbGpPWpGaD
Clofedanol—HRH1—Amine ligand-binding receptors—ADRA1A—polycystic ovary syndrome	0.0221	0.034	CbGpPWpGaD
Clofedanol—HRH1—Amine ligand-binding receptors—ADRB3—polycystic ovary syndrome	0.0213	0.0327	CbGpPWpGaD
Clofedanol—Clotrimazole—CYP17A1—polycystic ovary syndrome	0.0198	0.0569	CrCbGaD
Clofedanol—Clotrimazole—CYP11A1—polycystic ovary syndrome	0.0195	0.056	CrCbGaD
Clofedanol—Phenoxybenzamine—ADRA1D—polycystic ovary syndrome	0.0183	0.0527	CrCbGaD
Clofedanol—Phenoxybenzamine—ADRA1B—polycystic ovary syndrome	0.0157	0.045	CrCbGaD
Clofedanol—Doxepin—ADRA1D—polycystic ovary syndrome	0.0149	0.0429	CrCbGaD
Clofedanol—HRH1—Monoamine GPCRs—ADRB2—polycystic ovary syndrome	0.0137	0.021	CbGpPWpGaD
Clofedanol—Trimipramine—ADRA1B—polycystic ovary syndrome	0.0134	0.0384	CrCbGaD
Clofedanol—Promazine—ADRA1D—polycystic ovary syndrome	0.0133	0.0381	CrCbGaD
Clofedanol—Doxepin—ADRA1B—polycystic ovary syndrome	0.0127	0.0366	CrCbGaD
Clofedanol—Imipramine—ADRA1D—polycystic ovary syndrome	0.0116	0.0334	CrCbGaD
Clofedanol—Amitriptyline—ADRA1D—polycystic ovary syndrome	0.0115	0.0332	CrCbGaD
Clofedanol—HRH1—Amine ligand-binding receptors—ADRB2—polycystic ovary syndrome	0.0115	0.0176	CbGpPWpGaD
Clofedanol—Promazine—ADRA1B—polycystic ovary syndrome	0.0113	0.0325	CrCbGaD
Clofedanol—Benzphetamine—ADRA1A—polycystic ovary syndrome	0.011	0.0317	CrCbGaD
Clofedanol—Toremifene—CYP1A1—polycystic ovary syndrome	0.011	0.0315	CrCbGaD
Clofedanol—Phenoxybenzamine—ADRA1A—polycystic ovary syndrome	0.0105	0.0303	CrCbGaD
Clofedanol—Levomethadyl Acetate—CYP19A1—polycystic ovary syndrome	0.0101	0.029	CrCbGaD
Clofedanol—Clotrimazole—CYP19A1—polycystic ovary syndrome	0.0101	0.029	CrCbGaD
Clofedanol—Chlorpromazine—ADRA1B—polycystic ovary syndrome	0.00996	0.0286	CrCbGaD
Clofedanol—Imipramine—ADRA1B—polycystic ovary syndrome	0.00991	0.0285	CrCbGaD
Clofedanol—Amitriptyline—ADRA1B—polycystic ovary syndrome	0.00985	0.0283	CrCbGaD
Clofedanol—HRH1—G alpha (q) signalling events—PTAFR—polycystic ovary syndrome	0.00918	0.0141	CbGpPWpGaD
Clofedanol—Trimipramine—ADRA1A—polycystic ovary syndrome	0.009	0.0258	CrCbGaD
Clofedanol—HRH1—G alpha (q) signalling events—ADRA1D—polycystic ovary syndrome	0.00892	0.0137	CbGpPWpGaD
Clofedanol—HRH1—G alpha (q) signalling events—ADRA1B—polycystic ovary syndrome	0.00867	0.0133	CbGpPWpGaD
Clofedanol—Promethazine—ADRA1A—polycystic ovary syndrome	0.00866	0.0249	CrCbGaD
Clofedanol—Doxepin—ADRA1A—polycystic ovary syndrome	0.00858	0.0246	CrCbGaD
Clofedanol—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—PTAFR—polycystic ovary syndrome	0.00821	0.0126	CbGpPWpGaD
Clofedanol—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—ADRA1D—polycystic ovary syndrome	0.00797	0.0122	CbGpPWpGaD
Clofedanol—HRH1—Class A/1 (Rhodopsin-like receptors)—NPB—polycystic ovary syndrome	0.00779	0.012	CbGpPWpGaD
Clofedanol—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—ADRA1B—polycystic ovary syndrome	0.00776	0.0119	CbGpPWpGaD
Clofedanol—Promazine—ADRA1A—polycystic ovary syndrome	0.00762	0.0219	CrCbGaD
Clofedanol—HRH1—GPCRs, Class A Rhodopsin-like—PTGER3—polycystic ovary syndrome	0.00759	0.0116	CbGpPWpGaD
Clofedanol—HRH1—GPCRs, Class A Rhodopsin-like—LHCGR—polycystic ovary syndrome	0.00759	0.0116	CbGpPWpGaD
Clofedanol—HRH1—GPCRs, Class A Rhodopsin-like—PTAFR—polycystic ovary syndrome	0.0071	0.0109	CbGpPWpGaD
Clofedanol—HRH1—GPCRs, Class A Rhodopsin-like—ADRA1D—polycystic ovary syndrome	0.00689	0.0106	CbGpPWpGaD
Clofedanol—HRH1—IL-4 Signaling Pathway—IRS2—polycystic ovary syndrome	0.00685	0.0105	CbGpPWpGaD
Clofedanol—Chlorpromazine—ADRA1A—polycystic ovary syndrome	0.00671	0.0193	CrCbGaD
Clofedanol—HRH1—GPCRs, Class A Rhodopsin-like—ADRA1B—polycystic ovary syndrome	0.0067	0.0103	CbGpPWpGaD
Clofedanol—Imipramine—ADRA1A—polycystic ovary syndrome	0.00667	0.0192	CrCbGaD
Clofedanol—Amitriptyline—ADRA1A—polycystic ovary syndrome	0.00663	0.019	CrCbGaD
Clofedanol—HRH1—G alpha (q) signalling events—ADRA1A—polycystic ovary syndrome	0.00657	0.0101	CbGpPWpGaD
Clofedanol—HRH1—Class A/1 (Rhodopsin-like receptors)—LHCGR—polycystic ovary syndrome	0.0065	0.00998	CbGpPWpGaD
Clofedanol—HRH1—Class A/1 (Rhodopsin-like receptors)—PTGER3—polycystic ovary syndrome	0.0065	0.00998	CbGpPWpGaD
Clofedanol—Phenoxybenzamine—ADRB2—polycystic ovary syndrome	0.00627	0.018	CrCbGaD
Clofedanol—HRH1—G alpha (q) signalling events—GNRH1—polycystic ovary syndrome	0.00611	0.00938	CbGpPWpGaD
Clofedanol—HRH1—Class A/1 (Rhodopsin-like receptors)—PTAFR—polycystic ovary syndrome	0.00608	0.00933	CbGpPWpGaD
Clofedanol—HRH1—IL-4 Signaling Pathway—IRS1—polycystic ovary syndrome	0.00598	0.00918	CbGpPWpGaD
Clofedanol—Tamoxifen—CYP19A1—polycystic ovary syndrome	0.00596	0.0171	CrCbGaD
Clofedanol—HRH1—GPCR ligand binding—NPB—polycystic ovary syndrome	0.00593	0.0091	CbGpPWpGaD
Clofedanol—Methadone—CYP19A1—polycystic ovary syndrome	0.00591	0.017	CrCbGaD
Clofedanol—HRH1—Class A/1 (Rhodopsin-like receptors)—ADRA1D—polycystic ovary syndrome	0.0059	0.00906	CbGpPWpGaD
Clofedanol—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—ADRA1A—polycystic ovary syndrome	0.00588	0.00902	CbGpPWpGaD
Clofedanol—HRH1—Class A/1 (Rhodopsin-like receptors)—ADRA1B—polycystic ovary syndrome	0.00574	0.00881	CbGpPWpGaD
Clofedanol—HRH1—GPCRs, Class A Rhodopsin-like—FSHR—polycystic ovary syndrome	0.00556	0.00852	CbGpPWpGaD
Clofedanol—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—GNRH1—polycystic ovary syndrome	0.00547	0.00838	CbGpPWpGaD
Clofedanol—HRH1—GPCRs, Class A Rhodopsin-like—ADRA1A—polycystic ovary syndrome	0.00508	0.0078	CbGpPWpGaD
Clofedanol—HRH1—GPCR ligand binding—LHCGR—polycystic ovary syndrome	0.00495	0.0076	CbGpPWpGaD
Clofedanol—HRH1—GPCR ligand binding—PTGER3—polycystic ovary syndrome	0.00495	0.0076	CbGpPWpGaD
Clofedanol—HRH1—GPCRs, Class A Rhodopsin-like—ADRB3—polycystic ovary syndrome	0.00489	0.0075	CbGpPWpGaD
Clofedanol—HRH1—Class A/1 (Rhodopsin-like receptors)—FSHR—polycystic ovary syndrome	0.00476	0.0073	CbGpPWpGaD
Clofedanol—HRH1—GPCR ligand binding—PTAFR—polycystic ovary syndrome	0.00463	0.00711	CbGpPWpGaD
Clofedanol—HRH1—GPCR ligand binding—ADRA1D—polycystic ovary syndrome	0.0045	0.0069	CbGpPWpGaD
Clofedanol—Tamoxifen—CYP1A1—polycystic ovary syndrome	0.00439	0.0126	CrCbGaD
Clofedanol—HRH1—GPCR ligand binding—ADRA1B—polycystic ovary syndrome	0.00437	0.00671	CbGpPWpGaD
Clofedanol—HRH1—Class A/1 (Rhodopsin-like receptors)—ADRA1A—polycystic ovary syndrome	0.00435	0.00668	CbGpPWpGaD
Clofedanol—HRH1—GPCRs, Class A Rhodopsin-like—MTNR1B—polycystic ovary syndrome	0.00432	0.00663	CbGpPWpGaD
Clofedanol—HRH1—Class A/1 (Rhodopsin-like receptors)—ADRB3—polycystic ovary syndrome	0.00419	0.00643	CbGpPWpGaD
Clofedanol—HRH1—Class A/1 (Rhodopsin-like receptors)—LHB—polycystic ovary syndrome	0.00414	0.00635	CbGpPWpGaD
Clofedanol—HRH1—G alpha (q) signalling events—GHRL—polycystic ovary syndrome	0.00413	0.00633	CbGpPWpGaD
Clofedanol—HRH1—Class A/1 (Rhodopsin-like receptors)—GNRH1—polycystic ovary syndrome	0.00405	0.00621	CbGpPWpGaD
Clofedanol—HRH1—Class A/1 (Rhodopsin-like receptors)—MTNR1B—polycystic ovary syndrome	0.0037	0.00568	CbGpPWpGaD
Clofedanol—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—GHRL—polycystic ovary syndrome	0.00369	0.00566	CbGpPWpGaD
Clofedanol—HRH1—GPCR ligand binding—FSHR—polycystic ovary syndrome	0.00362	0.00556	CbGpPWpGaD
Clofedanol—HRH1—GPCR downstream signaling—NPB—polycystic ovary syndrome	0.00335	0.00514	CbGpPWpGaD
Clofedanol—HRH1—GPCR ligand binding—ADRA1A—polycystic ovary syndrome	0.00331	0.00509	CbGpPWpGaD
Clofedanol—HRH1—GPCR ligand binding—ADRB3—polycystic ovary syndrome	0.00319	0.0049	CbGpPWpGaD
Clofedanol—HRH1—GPCR ligand binding—LHB—polycystic ovary syndrome	0.00315	0.00484	CbGpPWpGaD
Clofedanol—HRH1—GPCR ligand binding—GNRH1—polycystic ovary syndrome	0.00308	0.00473	CbGpPWpGaD
Clofedanol—HRH1—Signaling by GPCR—NPB—polycystic ovary syndrome	0.00304	0.00467	CbGpPWpGaD
Clofedanol—HRH1—GPCR downstream signaling—PLEKHG5—polycystic ovary syndrome	0.00303	0.00465	CbGpPWpGaD
Clofedanol—HRH1—Signaling Pathways—ARHGAP30—polycystic ovary syndrome	0.00297	0.00455	CbGpPWpGaD
Clofedanol—HRH1—Signaling Pathways—ARHGAP23—polycystic ovary syndrome	0.00297	0.00455	CbGpPWpGaD
Clofedanol—HRH1—GPCR ligand binding—SCT—polycystic ovary syndrome	0.00295	0.00453	CbGpPWpGaD
Clofedanol—HRH1—GPCR ligand binding—MTNR1B—polycystic ovary syndrome	0.00282	0.00432	CbGpPWpGaD
Clofedanol—HRH1—GPCR downstream signaling—PTGER3—polycystic ovary syndrome	0.0028	0.00429	CbGpPWpGaD
Clofedanol—HRH1—GPCR downstream signaling—LHCGR—polycystic ovary syndrome	0.0028	0.00429	CbGpPWpGaD
Clofedanol—HRH1—Signaling by GPCR—PLEKHG5—polycystic ovary syndrome	0.00275	0.00422	CbGpPWpGaD
Clofedanol—HRH1—Class A/1 (Rhodopsin-like receptors)—GHRL—polycystic ovary syndrome	0.00273	0.00419	CbGpPWpGaD
Clofedanol—HRH1—GPCRs, Class A Rhodopsin-like—ADRB2—polycystic ovary syndrome	0.00264	0.00405	CbGpPWpGaD
Clofedanol—HRH1—GPCR downstream signaling—PTAFR—polycystic ovary syndrome	0.00262	0.00402	CbGpPWpGaD
Clofedanol—HRH1—Signaling by GPCR—PTGER3—polycystic ovary syndrome	0.00254	0.0039	CbGpPWpGaD
Clofedanol—HRH1—Signaling by GPCR—LHCGR—polycystic ovary syndrome	0.00254	0.0039	CbGpPWpGaD
Clofedanol—HRH1—GPCR downstream signaling—ADRA1D—polycystic ovary syndrome	0.00254	0.0039	CbGpPWpGaD
Clofedanol—HRH1—GPCR downstream signaling—ADRA1B—polycystic ovary syndrome	0.00247	0.00379	CbGpPWpGaD
Clofedanol—HRH1—Signaling by GPCR—PTAFR—polycystic ovary syndrome	0.00238	0.00365	CbGpPWpGaD
Clofedanol—HRH1—Signaling by GPCR—ADRA1D—polycystic ovary syndrome	0.00231	0.00354	CbGpPWpGaD
Clofedanol—HRH1—Class A/1 (Rhodopsin-like receptors)—ADRB2—polycystic ovary syndrome	0.00226	0.00347	CbGpPWpGaD
Clofedanol—HRH1—GPCR downstream signaling—PDE3B—polycystic ovary syndrome	0.00225	0.00345	CbGpPWpGaD
Clofedanol—HRH1—Signaling by GPCR—ADRA1B—polycystic ovary syndrome	0.00224	0.00344	CbGpPWpGaD
Clofedanol—HRH1—GPCR ligand binding—GHRL—polycystic ovary syndrome	0.00208	0.00319	CbGpPWpGaD
Clofedanol—HRH1—Signaling Pathways—FLT4—polycystic ovary syndrome	0.00206	0.00316	CbGpPWpGaD
Clofedanol—HRH1—GPCR downstream signaling—FSHR—polycystic ovary syndrome	0.00205	0.00314	CbGpPWpGaD
Clofedanol—HRH1—Signaling by GPCR—PDE3B—polycystic ovary syndrome	0.00204	0.00313	CbGpPWpGaD
Clofedanol—HRH1—GPCR downstream signaling—ADRA1A—polycystic ovary syndrome	0.00187	0.00287	CbGpPWpGaD
Clofedanol—HRH1—Signaling by GPCR—FSHR—polycystic ovary syndrome	0.00186	0.00285	CbGpPWpGaD
Clofedanol—HRH1—GPCR downstream signaling—ADRB3—polycystic ovary syndrome	0.0018	0.00277	CbGpPWpGaD
Clofedanol—HRH1—Signaling Pathways—NPB—polycystic ovary syndrome	0.0018	0.00276	CbGpPWpGaD
Clofedanol—HRH1—GPCR downstream signaling—LHB—polycystic ovary syndrome	0.00178	0.00273	CbGpPWpGaD
Clofedanol—HRH1—GPCR downstream signaling—GNRH1—polycystic ovary syndrome	0.00174	0.00267	CbGpPWpGaD
Clofedanol—HRH1—GPCR ligand binding—ADRB2—polycystic ovary syndrome	0.00172	0.00264	CbGpPWpGaD
Clofedanol—HRH1—Signaling by GPCR—ADRA1A—polycystic ovary syndrome	0.0017	0.00261	CbGpPWpGaD
Clofedanol—HRH1—GPCR downstream signaling—SCT—polycystic ovary syndrome	0.00167	0.00256	CbGpPWpGaD
Clofedanol—HRH1—Signaling by GPCR—ADRB3—polycystic ovary syndrome	0.00164	0.00251	CbGpPWpGaD
Clofedanol—HRH1—Signaling Pathways—PLEKHG5—polycystic ovary syndrome	0.00163	0.0025	CbGpPWpGaD
Clofedanol—HRH1—Signaling by GPCR—LHB—polycystic ovary syndrome	0.00162	0.00248	CbGpPWpGaD
Clofedanol—HRH1—GPCR ligand binding—GNAS—polycystic ovary syndrome	0.0016	0.00245	CbGpPWpGaD
Clofedanol—HRH1—GPCR downstream signaling—MTNR1B—polycystic ovary syndrome	0.00159	0.00244	CbGpPWpGaD
Clofedanol—HRH1—Signaling by GPCR—GNRH1—polycystic ovary syndrome	0.00158	0.00243	CbGpPWpGaD
Clofedanol—HRH1—Signaling by GPCR—SCT—polycystic ovary syndrome	0.00152	0.00233	CbGpPWpGaD
Clofedanol—HRH1—Signaling Pathways—PTGER3—polycystic ovary syndrome	0.0015	0.0023	CbGpPWpGaD
Clofedanol—HRH1—Signaling Pathways—LHCGR—polycystic ovary syndrome	0.0015	0.0023	CbGpPWpGaD
Clofedanol—HRH1—Signaling by GPCR—MTNR1B—polycystic ovary syndrome	0.00145	0.00222	CbGpPWpGaD
Clofedanol—HRH1—Class A/1 (Rhodopsin-like receptors)—POMC—polycystic ovary syndrome	0.00141	0.00217	CbGpPWpGaD
Clofedanol—HRH1—Signaling Pathways—PTAFR—polycystic ovary syndrome	0.0014	0.00215	CbGpPWpGaD
Clofedanol—HRH1—Signaling Pathways—ADRA1D—polycystic ovary syndrome	0.00136	0.00209	CbGpPWpGaD
Clofedanol—HRH1—Signaling Pathways—ADRA1B—polycystic ovary syndrome	0.00133	0.00203	CbGpPWpGaD
Clofedanol—HRH1—Signaling Pathways—INHBB—polycystic ovary syndrome	0.00129	0.00198	CbGpPWpGaD
Clofedanol—HRH1—Signaling Pathways—PDE3B—polycystic ovary syndrome	0.00121	0.00185	CbGpPWpGaD
Clofedanol—HRH1—GPCR downstream signaling—GHRL—polycystic ovary syndrome	0.00118	0.0018	CbGpPWpGaD
Clofedanol—HRH1—Signaling Pathways—FSHR—polycystic ovary syndrome	0.0011	0.00169	CbGpPWpGaD
Clofedanol—HRH1—GPCR ligand binding—POMC—polycystic ovary syndrome	0.00108	0.00165	CbGpPWpGaD
Clofedanol—HRH1—Signaling by GPCR—GHRL—polycystic ovary syndrome	0.00107	0.00164	CbGpPWpGaD
Clofedanol—HRH1—Signaling Pathways—RACGAP1—polycystic ovary syndrome	0.00103	0.00158	CbGpPWpGaD
Clofedanol—HRH1—Signaling Pathways—ADRA1A—polycystic ovary syndrome	0.001	0.00154	CbGpPWpGaD
Clofedanol—HRH1—Signaling Pathways—FST—polycystic ovary syndrome	0.000979	0.0015	CbGpPWpGaD
Clofedanol—HRH1—GPCR downstream signaling—ADRB2—polycystic ovary syndrome	0.000974	0.00149	CbGpPWpGaD
Clofedanol—HRH1—Signaling Pathways—ADRB3—polycystic ovary syndrome	0.000967	0.00148	CbGpPWpGaD
Clofedanol—HRH1—Signaling Pathways—LHB—polycystic ovary syndrome	0.000956	0.00147	CbGpPWpGaD
Clofedanol—HRH1—Signaling Pathways—GNRH1—polycystic ovary syndrome	0.000934	0.00143	CbGpPWpGaD
Clofedanol—HRH1—Signaling Pathways—AKR1C1—polycystic ovary syndrome	0.000905	0.00139	CbGpPWpGaD
Clofedanol—HRH1—GPCR downstream signaling—GNAS—polycystic ovary syndrome	0.000903	0.00139	CbGpPWpGaD
Clofedanol—HRH1—Signaling Pathways—SCT—polycystic ovary syndrome	0.000896	0.00137	CbGpPWpGaD
Clofedanol—HRH1—Signaling by GPCR—ADRB2—polycystic ovary syndrome	0.000884	0.00136	CbGpPWpGaD
Clofedanol—HRH1—Signaling Pathways—MTNR1B—polycystic ovary syndrome	0.000854	0.00131	CbGpPWpGaD
Clofedanol—HRH1—Signaling Pathways—FGF18—polycystic ovary syndrome	0.00084	0.00129	CbGpPWpGaD
Clofedanol—HRH1—Signaling Pathways—RBP4—polycystic ovary syndrome	0.000833	0.00128	CbGpPWpGaD
Clofedanol—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—polycystic ovary syndrome	0.000829	0.00127	CbGpPWpGaD
Clofedanol—HRH1—Signaling by GPCR—GNAS—polycystic ovary syndrome	0.00082	0.00126	CbGpPWpGaD
Clofedanol—HRH1—Signaling Pathways—YAP1—polycystic ovary syndrome	0.000777	0.00119	CbGpPWpGaD
Clofedanol—HRH1—Signaling Pathways—GAB1—polycystic ovary syndrome	0.000767	0.00118	CbGpPWpGaD
Clofedanol—HRH1—Signaling Pathways—INSR—polycystic ovary syndrome	0.000733	0.00112	CbGpPWpGaD
Clofedanol—HRH1—Signaling Pathways—AKR1C3—polycystic ovary syndrome	0.000697	0.00107	CbGpPWpGaD
Clofedanol—HRH1—Signaling Pathways—TNRC6B—polycystic ovary syndrome	0.000686	0.00105	CbGpPWpGaD
Clofedanol—HRH1—Signaling Pathways—PGR—polycystic ovary syndrome	0.000679	0.00104	CbGpPWpGaD
Clofedanol—HRH1—Signaling Pathways—GHRL—polycystic ovary syndrome	0.000631	0.000968	CbGpPWpGaD
Clofedanol—HRH1—Signaling Pathways—PLAT—polycystic ovary syndrome	0.000631	0.000968	CbGpPWpGaD
Clofedanol—HRH1—GPCR downstream signaling—POMC—polycystic ovary syndrome	0.000608	0.000933	CbGpPWpGaD
Clofedanol—HRH1—Signaling Pathways—ATF1—polycystic ovary syndrome	0.000602	0.000924	CbGpPWpGaD
Clofedanol—HRH1—Signaling Pathways—TCF7L2—polycystic ovary syndrome	0.000587	0.000901	CbGpPWpGaD
Clofedanol—HRH1—GPCR downstream signaling—AKT2—polycystic ovary syndrome	0.000584	0.000897	CbGpPWpGaD
Clofedanol—HRH1—Signaling Pathways—NGFR—polycystic ovary syndrome	0.000556	0.000852	CbGpPWpGaD
Clofedanol—HRH1—Signaling by GPCR—POMC—polycystic ovary syndrome	0.000552	0.000847	CbGpPWpGaD
Clofedanol—HRH1—Signaling Pathways—PRL—polycystic ovary syndrome	0.000551	0.000845	CbGpPWpGaD
Clofedanol—HRH1—Signaling by GPCR—AKT2—polycystic ovary syndrome	0.000531	0.000814	CbGpPWpGaD
Clofedanol—HRH1—Signaling Pathways—ADRB2—polycystic ovary syndrome	0.000522	0.000801	CbGpPWpGaD
Clofedanol—HRH1—Signaling Pathways—GNAS—polycystic ovary syndrome	0.000484	0.000743	CbGpPWpGaD
Clofedanol—HRH1—Signaling Pathways—NCOR1—polycystic ovary syndrome	0.000461	0.000708	CbGpPWpGaD
Clofedanol—HRH1—Signaling Pathways—NRG1—polycystic ovary syndrome	0.000453	0.000695	CbGpPWpGaD
Clofedanol—HRH1—Signaling Pathways—IRS2—polycystic ovary syndrome	0.000388	0.000595	CbGpPWpGaD
Clofedanol—HRH1—Signaling Pathways—LEP—polycystic ovary syndrome	0.00038	0.000582	CbGpPWpGaD
Clofedanol—HRH1—Signaling Pathways—IRS1—polycystic ovary syndrome	0.000339	0.00052	CbGpPWpGaD
Clofedanol—HRH1—Signaling Pathways—POMC—polycystic ovary syndrome	0.000326	0.0005	CbGpPWpGaD
Clofedanol—HRH1—Signaling Pathways—INS—polycystic ovary syndrome	0.000324	0.000498	CbGpPWpGaD
Clofedanol—HRH1—Signaling Pathways—IGF1—polycystic ovary syndrome	0.000314	0.000481	CbGpPWpGaD
Clofedanol—HRH1—Signaling Pathways—AKT2—polycystic ovary syndrome	0.000313	0.000481	CbGpPWpGaD
Clofedanol—HRH1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	0.000298	0.000457	CbGpPWpGaD
Clofedanol—HRH1—Signaling by GPCR—IL6—polycystic ovary syndrome	0.00024	0.000368	CbGpPWpGaD
Clofedanol—HRH1—Signaling Pathways—VEGFA—polycystic ovary syndrome	0.000205	0.000314	CbGpPWpGaD
Clofedanol—HRH1—Signaling Pathways—IL6—polycystic ovary syndrome	0.000142	0.000217	CbGpPWpGaD
